中国全科医学2017，Vol.20Issue(20)：2469-2473,5.DOI:10.3969/j.issn.1007-9572.2017.20.009
替吉奥治疗卡培他滨耐药转移性乳腺癌的疗效分析
Therapeutic Efficiency of Tegafur,Gimeracil and Oteracil Potassium for Metastatic Breast Cancer Resistant to Capecitabine
摘要
Abstract
Objective The purpose of this study is to analyze retrospectively the therapeutic efficiency and safety of tegafur,gimeracil and oteracil potassium monotherapy in patients with metastatic breast cancer resistant to capecitabine monotherapy.Methods We retrospectively ananlyzed the clinical data of 22 cases of patients with metastatic breast cancer in the Department of Medical Oncology,the Affiliated Hospital of School of Medicine Ningbo University between November 2011 and May 2015.All patients accepted capecitabine monotherapy,then they all accepted tegafur,gimeracil and oteracil potassium monotherapy after resistant to capecitabine until tumor progression,intolerable side effects and toxicity or refusal of treatment.The therapeutic efficiency of tegafur,gimeracil and oteracil potassium was evaluated according to the Response Evaluation Criteria in Solid Tumors(RECIST),and then the time to progression and overall survival were observed.The pain score and CA153 value were also recorded.Side effects and toxicities were assessed according to the common terminology criteria for adverse events(CTCAE v4.02) issued by the National Cancer Institute.Results Five patients had partial remission,12 had stable disease,and 5 had disease progress in 22 patients with capecitabine-resistant metastatic breast cancer after tegafur,gimeracil and oteracil potassium treatment.Objective response rate was 22.7%(5/22),clinical benefit response was 77.3%(17/22).Median time to progression was 113 days(22-218 days),median overall survival was 20.2 months(3.8-38.2 momths).A total of 15 patients complained of pain before tegafur,gimeracil and oteracil potassium therapy.Pain relief happened in 10 cases without the increase of analgesic drugs dosage after therapy.Compared with the CA153 value on the beginning of tegafur,gimeracil and oteracil potassium therapy,the lowest CA153 value in the course of therapy decreased signifcantly〔(174.8±67.4)U/ml vs.(102.8±69.7)U/ml,t=4.174,P=0.001〕.The toxic side effects of tegafur,gimeracil and oteracil potassium were well tolerated,and major adverse reactions included anorexia〔59.1%(13/22)〕,nauseas〔50.0%(11/22)〕,fatigue〔45.5%(10/22)〕,neutropenia〔45.5%(10/22)〕,anemia〔40.9%(9/22)〕,diarrhea〔36.4%(8/22)〕,hand-foot syndrome〔27.3%(6/22)〕,transaminase elevation〔22.7%(5/22)〕 and vomiting〔18.2%(4/22)〕et al.Most adverse reactions were Grade Ⅰ-Ⅱ adverse events,Grade Ⅲ adverse events only occurred in 3 cases.Conclusion Tegafur,gimeracil and oteracil potassium monotherapy is effective and well-tolerated in patients with metastatic breast cancer resistant to capecitabine monotherapy.So tegafur,gimeracil and oteracil potassium monotherapy is a selective regime treatment for patients with metastatic breast cancer after they were resistant to capecitabine monotherapy.关键词
乳腺肿瘤/替吉奥/卡培他滨/抗肿瘤联合化疗方案Key words
Breast neoplasms/Tegafur,gimeracil and oteracil potassium/Capecitabine/Antineoplastic combined chemotherapy protocols分类
医药卫生引用本文复制引用
王少敏,叶孟,倪曙民..替吉奥治疗卡培他滨耐药转移性乳腺癌的疗效分析[J].中国全科医学,2017,20(20):2469-2473,5.基金项目
宁波大学校级科研项目(XYY15007) （XYY15007）
